TB-500
FDA identifies TB-500 as a specific thymosin beta-4 fragment and notes missing human exposure data.
Keep the safety limits visible.
The FDA source identifies thymosin beta-4 fragment LKKTETQ as also known as TB-500. A fragment should not be silently equated with the full-length thymosin beta-4 molecule or every seller product using a similar name.
FDA identifies possible immunogenicity risks for certain routes from aggregation and impurities. It says it has not identified human exposure data for drug products containing this fragment.
The agency lacks important safety information, including whether administration would cause harm. This note does not establish tissue-repair or recovery benefits, give dosing instructions or link to sellers.
Interpretation is limited to the source linked above. Independent medical review pending.